{
    "clinical_study": {
        "@rank": "82161", 
        "acronym": "RESERVOIR", 
        "arm_group": [
            {
                "arm_group_label": "Polymer-Based Everolimus-Eluting Stent", 
                "arm_group_type": "Active Comparator", 
                "description": "Polymer-Based Everolimus-Eluting Stent"
            }, 
            {
                "arm_group_label": "Polymer-Free Amphilimus-Eluting Stent", 
                "arm_group_type": "Experimental", 
                "description": "Reservoir-Based Polymer-Free Amphilimus-Eluting Stent"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a prospective, randomized controlled, single blind, two-arm, multicenter\n      clinical evaluation.\n\n      Diabetic patients (n=112) with de novo coronary artery disease will be randomized to one of\n      the 2 treatment arms: 1) Reservoir-Based Polymer-Free Amphilimus-Eluting Stent or 2)\n      Polymer-Based Everolimus-Eluting Stent.\n\n      The purpose of this study is to determine whether Polymer-Free Amphilimus-Eluting Stent\n      implantation is effective in reducing neointimal hyperplasia as compared to Polymer-Based\n      Everolimus-Eluting Stent in diabetic patients, using Optical Coherence Tomography (OCT) as\n      the primary imaging modality."
        }, 
        "brief_title": "Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Diabetes Mellitus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Diabetes Mellitus"
            ]
        }, 
        "detailed_description": {
            "textblock": "In patients with diabetes mellitus (DM), drug eluting stents (DES) have been shown to be\n      associated with greater neointimal suppression than bare-metal stents. However, there is an\n      ongoing debate on the optimal drug-eluting stent in diabetic patients.\n\n      This study is a prospective, randomized controlled, single blind, two-arm, multicenter\n      clinical evaluation.\n\n      Diabetic patients (n=112) with de novo coronary artery disease will be randomized to one of\n      the 2 treatment arms: 1) Reservoir-Based Polymer-Free Amphilimus-Eluting Stent or 2)\n      Polymer-Based Everolimus-Eluting Stent.\n\n      The purpose of this study is to determine whether Polymer-Free Amphilimus-Eluting Stent\n      implantation is effective in reducing neointimal hyperplasia as compared to Polymer-Based\n      Everolimus-Eluting Stent in diabetic patients, using Optical Coherence Tomography (OCT) as\n      the primary imaging modality."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Clinical Inclusion Criteria:\n\n          -  Subject is eligible for PCI.\n\n          -  Subject has symptomatic coronary artery disease (stable/unstable angina or Non-ST\n             elevation myocardial infarction).\n\n          -  Subject has known DM.\n\n        Angiographic Inclusion Criteria:\n\n          -  Presence of 1 or 2 de novo native coronary artery lesions (maximum 1 lesion per\n             epicardial coronary artery), with a visual estimation stenosis \u2265 50%.\n\n          -  Target lesion length 12-25mm, reference diameter 2.5-3.5mm.\n\n        Clinical Exclusion Criteria:\n\n          -  ST-segment elevation myocardial infarction <48h\n\n          -  Presence of cardiogenic shock pre-procedure\n\n          -  Contra-indications to dual antiplatelet therapy for 12 months\n\n          -  Left Ventricular Ejection Fraction \u226430%\n\n          -  GFR<30 ml/min/m2\n\n          -  Target vessel has been treated previously\n\n          -  Platelet count <75000/mm3 or >700000/mm3\n\n          -  Immunosuppressive therapy\n\n          -  Has received or waiting list for any transplant\n\n          -  Life-threatening disease with a life expectancy of < 12 months\n\n          -  Pregnant or breast feeding patient\n\n          -  Inability to provide informed consent\n\n        Angiographic Exclusion Criteria:\n\n          -  TIMI flow \u2264 1 prior to guide wire crossing\n\n          -  There is an additional lesion within the target vessel planned to be treated within\n             the next 12 months\n\n          -  Target vessel is a saphenous vein graft\n\n          -  Target vessel is the left main, ostial LAD and/or ostial LCX.\n\n          -  Prior PCI of the target lesion (restenosis)\n\n          -  Lesion cannot be covered by a single stent (unplanned bailout stenting is allowed)\n\n          -  Involved side branch \u22652.5mm by visual estimation\n\n          -  Rotablator, ELCA or brachytherapy\n\n          -  Severe calcification of target lesion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710748", 
            "org_study_id": "SEC-RES-2012-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Polymer-Based Everolimus-Eluting Stent", 
                "description": "Polymer-Based Everolimus-Eluting Stent", 
                "intervention_name": "Polymer-Based Everolimus-Eluting Stent", 
                "intervention_type": "Device", 
                "other_name": "Xience Coronary Stent System"
            }, 
            {
                "arm_group_label": "Polymer-Free Amphilimus-Eluting Stent", 
                "description": "Reservoir-Based Polymer-Free Amphilimus-Eluting Stent", 
                "intervention_name": "Polymer-Free Amphilimus-Eluting Stent", 
                "intervention_type": "Device", 
                "other_name": "Cre8 Coronary Stent System"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Percutaneous coronary intervention", 
            "Drug eluting stent", 
            "Neointimal hyperplasia", 
            "Diabetes Mellitus"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Universitari de Bellvitge"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednic i Provincial"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednico San Carlos"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murcia", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Virgen de la Arrixaca"
                }
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial", 
        "overall_official": {
            "affiliation": "Spanish Society of Cardiology", 
            "last_name": "Rafael Romaguera, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is assessed by Optical Coherence Tomography. It is defined as neointimal hyperplasia volume (mm3) divided by the stent volume multiplied by 100.", 
            "measure": "Neointimal hyperplasia volume obstruction", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710748"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Spanish Society of Cardiology", 
            "investigator_full_name": "Dr Rafael Romaguera", 
            "investigator_title": "Dr. Rafael Romaguera", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "This endpoint is assessed by Optical Coherence Tomography. Struts are classified as uncovered if any part of the strut is visibly exposed to the lumen, or covered if a layer of tissue is visible over all the reflecting surfaces.", 
                "measure": "Percentage of uncovered struts", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "This endpoint is assessed by Optical Coherence Tomography. Apposition is assessed strut by strut by measuring the distance between the strut marker and the lumen contour. Struts with distance to lumen contour larger than the sum of strut + polymer thickness are considered malapposed. This results in incomplete strut apposition thresholds of 89 \u00b5m for the Xience Prime and 80 \u00b5m for the Cre8 stent. Struts located at the ostium of side branches, with no vessel wall behind, are excluded from the analysis of apposition.", 
                "measure": "Percentage of malapposed struts", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }, 
            {
                "description": "This endpoint is assessed by Optical Coherence Tomography. Percentage of NIH cross-sectional obstruction is defined as the NIH area (mm2) divided by the stent area multiplied by 100.", 
                "measure": "Maximum percentage of NIH cross-sectional obstruction", 
                "safety_issue": "No", 
                "time_frame": "9 months"
            }, 
            {
                "description": "Death related to cardiac causes; if the cause of death cannot be determined, it will be also categorized as cardiac.", 
                "measure": "Cardiac death", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Stent thrombosis is considered according to the Academic Research Consortium definitions", 
                "measure": "Probable or definite stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Target vessel failure is defined as a composite endpoint of cardiac death, target vessel myocardial infarction and clinically indicated revascularization of the target vessel.", 
                "measure": "Target vessel failure", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Spanish Society of Cardiology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Spanish Society of Cardiology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}